OTC drugs
|
Co-insurance
|
-
|
Liebowitz [32] (US, ES, CD, R)
|
|
Insurance coverage
| | |
|
Supplementary (vs. none)
|
+
|
Caussat and Glaude [34] (FR, OS, CD, R)
|
|
Supplementary (vs. none)
|
-
|
Stuart and Grana [33] (US, OS, CD, R)
|
|
Prescription limit
|
+
|
Cox et al. [35] (US, OS, CD, R)
|
physician services
|
Co-payment
|
-
|
Anis et al. [129] (CA, OS, PD, R); Balkrishnan et al. [130] (US, NS, PD, R); Lauterbach et al. [131] (GE, OS, CD, R); Winkelmann [132] (GE, NS, PD, R); Winkelmann [133] (GE, NS, CD, R)
|
|
Co-payment
|
0
|
Gardner et al. [29] (US, NS, TD, R)
|
|
Multi-tier formulary (vs. 1- or 2-tiers)
|
0
|
Motheral and Fairman [28] (US, NS, CD, R)
|
|
Reference pricing
|
-
|
Hazlet and Blough [36] (CA, NS, TD, R)
|
|
Mixed system
|
+
|
Li et al. [31] (CA, NS, PD, R)
|
|
Change from
| | |
|
co-insurance to deductible and co-insurance
|
0
|
Pilote et al. [30] (CA, NS, CD, R)
|
|
Insurance coverage
| | |
|
Public Supplementary (vs. private)
|
+
|
Raynaud [134] (FR, OS, CD, R)
|
|
Reimbursement limit
|
-
|
Hsu et al. [135] (US, OS, PD, R)
|
outpatient services
|
Co-payment
|
+
|
Balkrishnan et al. [130] (US, NS, PD, R)
|
|
Mixed system
|
+
|
Gaynor et al. [99] (US, OS, PD, R)
|
|
Insurance coverage
| | |
|
Public supplementary (vs. none)
|
+
|
Raynaud [134] (FR, OS, CD, R)
|
inpatient services
|
Co-payment
|
+
|
Anis et al. [129] (CA, OS, PD, R); Atella et al. [76] (IT, NS, CD, R); Balkrishnan et al. [130] (US, NS, PD, R)
|
|
Co-payment
|
0
|
Gardner et al. [29] (US, NS, TD, R)
|
|
Reference pricing
|
0
|
Hazlet and Blough [36] (CA, NS, TD, R)
|
|
Multi-tier formulary (vs. 1- or 2-tiers)
|
0
|
Motheral and Fairman [28] (US, NS, CD, R)
|
|
Mixed system
|
0
|
Gaynor et al. [99] (US, OS, PD, R)
|
|
Insurance coverage
| | |
|
Supplementary (vs. none)
|
-
|
Schoen et al. [74] (US, NS, CD, NR)
|
|
Public supplementary drug (vs. private)
|
-
|
Lingle et al. [136] (US, OS, CD, R)
|
|
Prescription limit
|
0
|
Soumerai et al. [38] (US, NS, TD, R)
|
|
Prescription limit
|
+
|
Soumerai et al. [37] (US, NS, TD, R)
|
|
Reimbursement limit
|
+
|
Hsu et al. [135] (US, OS, PD, R)
|
ER visits
|
Multi-tier formulary (vs. 1- or 2-tiers)
|
0
|
Motheral and Fairman [28] (US, NS, CD, R)
|
|
Reference pricing
|
+
|
Hazlet and Blough [36] (CA, NS, TD, R)
|
|
Change from
| | |
|
co-payment to co-insurance and annual maximum
|
+
|
Tamblyn et al. [72] (CA, NS, TD, R)
|
|
co-insurance to deductible and co-insurance
|
0
|
Pilote et al. [30] (CA, NS, CD, R)
|
|
Reimbursement limit
|
+
|
Hsu et al. [135] (US, OS, PD, R)
|
|
Prescription limit
|
+
|
Soumerai et al. [37] (US, NS, TD, R)
|
emergency mental health services
|
Prescription limit
|
+
|
Soumerai et al. [38] (US, NS, TD, R)
|
nursing home admissions
|
Prescription limit
|
+
|
Soumerai et al. [38] (US, NS, TD, R)
|